Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - hepatitis a virus, quantity: 50 u/ml - injection - excipient ingredients: borax; water for injections; sodium chloride; aluminium - vaqta is indicated for active pre-exposure prophylaxis against disease caused by hepatitis a virus in persons 12 months of age and older. primary immunisation should be given at least 2 weeks prior to expected exposure to hepatitis a virus. individuals who are or will be increased risk of infection include: travellers to areas of intermediate or high endemicity for hepatitis a. persons for whom hepatitis a is an occupational hazard. employee of child day-care centers. certain institutional workers (eg. caretakers for the intellectually disabled). health workers and teachers in remote aboriginal and torres strait islander communities. nursing staff and other health care workers in contact with patients in paediatric wards and infectious disease wards. sewerage workers. recipients of blood products. individuals with chronic liver disease and those who have had a liver transplant. homosexually active males. human immunodeficiency virus (hiv)-infected adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - hepatitis a virus, quantity: 50 u/ml - injection - excipient ingredients: sodium chloride; borax; water for injections; aluminium - vaqta is indicated for active pre-exposure prophylaxis against disease caused by hepatitis a virus in persons 12 months of age and older. primary immunisation should be given at least 2 weeks prior to expected exposure to hepatitis a virus. individuals who are or will be increased risk of infection include: travellers to areas of intermediate or high endemicity for hepatitis a. persons for whom hepatitis a is an occupational hazard. employee of child day-care centers. certain institutional workers (eg. caretakers for the intellectually disabled). health workers and teachers in remote aboriginal and torres strait islander communities. nursing staff and other health care workers in contact with patients in paediatric wards and infectious disease wards. sewerage workers. recipients of blood products. individuals with chronic liver disease and those who have had a liver transplant. homosexually active males. human immunodeficiency virus (hiv)-infected adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - coxiella burnetii, quantity: 5 microgram/ml - injection - excipient ingredients: sodium chloride; monobasic sodium phosphate dihydrate; thiomersal; water for injections; dibasic sodium phosphate dodecahydrate - q-vax is indicated for the immunisation of susceptible adults at identifiable risk of infection with q fever. abattoir workers (and those closely associated with the meat industry), farmers, veterinarians, stockyard workers, shearers, animal transporters and many others exposed to cattle, sheep or goats or their products should be considered for vaccination. note: q fever has also occurred among persons culling and processing kangaroos and laboratory personnel handling potentially infected veterinary specimens, or visiting abattoirs, are at risk.

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - coxiella burnetii, quantity: 50 microgram/ml - injection - excipient ingredients: monobasic sodium phosphate dihydrate; thiomersal; dibasic sodium phosphate dodecahydrate; water for injections; sodium chloride - q-vax is indicated for the immunisation of susceptible adults at identifiable risk of infection with q fever. abattoir workers (and those closely associated with the meat industry), farmers, veterinarians, stockyard workers, shearers, animal transporters and many others exposed to cattle, sheep or goats or their products should be considered for vaccination. note: q fever has also occurred among persons culling and processing kangaroos and laboratory personnel handling potentially infected veterinary specimens, or visiting abattoirs, are at risk.

Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - irinotecan hydrochloride trihydrate, quantity: 5 mg/ml - injection, concentrated - excipient ingredients: distearoylphosphatidylcholine; cholesterol; sodium methoxy peg-40-carbonyl-distearoylphosphatidylethanolamine; hepes; sodium chloride; water for injections; sucrosofate - onivyde is indicated:,? in combination with oxaliplatin and 5 fluorouracil (5 fu) and leucovorin (lv) for the first-line treatment of metastatic pancreatic adenocarcinoma.,? in combination with 5-fu and lv for the treatment of metastatic pancreatic adenocarcinoma after disease progression following gemcitabine-based therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

global medical solutions australia pty limited t/a radpharm scientific - perflutren, quantity: 1.1 mg/ml - injection, suspension - excipient ingredients: sodium chloride; propylene glycol; water for injections; dipalmitoylphosphatidylcholine; n-(methoxy-peg-5000 carbamoyl)-dipalmitoylphosphatidylethanolamine sodium; sodium dipalmitoylphosphatidate; glycerol; dibasic sodium phosphate heptahydrate; monobasic sodium phosphate monohydrate - this medicinal product is for diagnostic use only. definity is indicated for use in patients in contrast-enhanced diagnostic ultrasound imaging to improve the characterization of focal lesions of the liver and kidney. definity is indicated for use in patients with suboptimal echocardiograms to provide opacification of cardiac chambers, improvement of left ventricular endocardial border delineation and assessment of regional wall at both rest and stress.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - tetanus toxoid, quantity: 20 microgram/ml; meningococcal polysaccharide group c, quantity: 20 microgram/ml - injection, suspension - excipient ingredients: sodium chloride; water for injections; aluminium hydroxide hydrate - neisvac-c vaccine is indicated for active immunisation of children from 8 weeks of age, adolescents and adults, for the prevention of invasive disease caused by neisseria meningitidis serogroup c.

Australia - English - Department of Health (Therapeutic Goods Administration)

medsurge pharma pty ltd - sodium nitroprusside - injection, concentrated - excipient ingredients: water for injections - - immediate reduction of blood pressure in patients with hypertensive crises. concomitant oral antihypertensive medication should be started while the hypertensive emergency is being brought under control with sodium nitroprusside. - producing controlled hypotension during anaesthesia in order to reduce bleeding in surgical procedures where surgeon and anaesthetist deem it appropriate. - short term therapy of cardiac failure, to enhance cardiac output and lower myocardial oxygen requirements. patients should be commenced on oral therapy as soon as possible.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - iopromide, quantity: 768.86 mg/ml - injection, solution - excipient ingredients: dilute hydrochloric acid; sodium calcium edetate; trometamol; water for injections; sodium hydroxide - ultravist is indicated for all angiographic and urographic examinations and for contrast enhancement in computerised tomography.,ultravist 300 or 370 is indicated for use in contrast-enhanced mammography (cem) in adults, to visualise known or suspected lesions of the breast as an adjunct to mammography (with or without ultrasound).

Australia - English - Department of Health (Therapeutic Goods Administration)

emcure pharmaceuticals pty ltd - sodium nitroprusside, quantity: 50 mg - injection, concentrated - excipient ingredients: water for injections - sodium nitroprusside concentrated injection is indicated for: ,1. immediate reduction of blood pressure in patients with hypertensive crises. concomitant oral antihypertensive medication should be started while the hypertensive emergency is being brought under control with sodium nitroprusside. ,2. producing controlled hypotension during anaesthesia in order to reduce bleeding in surgical procedures where surgeon and anaesthetist deem it appropriate. ,3. short term therapy of cardiac failure, to enhance cardiac output and lower myocardial oxygen requirements. patients should be commenced on oral therapy as soon as possible.